Name: | cetuximab |
---|---|
PubChem Substance ID: | 17397595 |
Synonyms: |
Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (genetical recombination) (JAN); D03455; Cetuximab (USAN); Cetuximab; 205923-56-4; Erbitux
|
Name: | cetuximab |
---|---|
Name (isomeric): | DB00002 |
Drug Type: | biotech |
Synonyms: |
IMC-C225; Anti EGFR
|
Brand: | Erbitux |
Category: | Antineoplastic Agents |
CAS number: | 205923-56-4 |
Indication: | For treatment of EGFR-expressing metastatic colorectal cancer in patients who are refractory to other irinotecan-based chemotherapy regimens. Cetuximab is also indicated for treatment of squamous cell carcinoma of the head and neck in conjucntion with radiation therapy. |
---|---|
Pharmacology: |
Used in the treatment of colorectal cancer, cetuximab binds specifically to the epidermal growth factor receptor (EGFr, HER1, c-ErbB-1) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor...
show more » |
Mechanism of Action: | Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread. |
Half Life: | 114 hrs |
Toxicity: | Single doses of cetuximab higher than 500 mg/m2 have not been tested. There is no experience with overdosage in human clinical trials. |
Affected organisms: | Humans and other mammals |